A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma

CTO - 6100
Cancer - Pancreatic
  1. Adults at least 18 years of age
  2. Histologic proof of primary head of pancreas invasive adenocarcinoma managed with a potentially curative resection (i.e. removal of all gross tumor) involving a classic (Whipple) or a pylorus preserving pancreaticoduodenectomy
Open
Tiffany Pearce